(Q38073096)

28 August 2017

1 reference

title

Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

1 reference

28 August 2017

I-K Choi

1 reference

28 August 2017

publication date

11 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

70-76

1 reference

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Evolution of oncolytic adenovirus for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Armed replicating adenoviruses for cancer virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Use of replicating oncolytic adenoviruses in combination therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Multigene expression from a replicating adenovirus using native viral promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Oncolytic (replication-competent) adenoviruses as anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Cancer selective adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Blood clearance rates of adenovirus type 5 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Overview of interleukin-2 function, production and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

21 January 2018

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

In situ gene therapy for prostate cancer: immunomodulatory approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Interleukin-12: biological properties and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Cytokine gene-mediated immunotherapy: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Facets of heat shock protein 70 show immunotherapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Radiation-induced bystander signalling in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Radiation-induced bystander effects--implications for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

T-cell responses to survivin in cancer patients undergoing radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Alteration of tumour response to radiation by interleukin-2 gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

p53 and brain tumors: from gene mutations to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Prodrug activation enzymes in cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

Treatment of metastatic head and neck cancer: chemotherapy and novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Biochemical studies on adenovirus multiplication. II. Kinetics of nucleic acid and protein synthesis in suspension cultures

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

ONYX-015: clinical data are encouraging

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

IL-12 deaths: explanation and a puzzle

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

The role of the CD28 receptor during T cell responses to antigen

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.95

7 January 2021

Identifiers

DOI

10.1038/CGT.2012.95

1 reference

28 August 2017

1 reference